冠状动脉CT血管造影中冠状动脉周围脂肪组织衰减作为心血管风险标志物:系统综述与荟萃分析
该研究系统检索了截至2025年6月的纵向CCTA研究,纳入17项研究共57862例,其中7个队列(5922例)进入基于HU的荟萃分析。结果显示PCAT衰减每增加5 HU,MACE风险增加(HR 1.29,95%CI 1.09-1.53),且在不同随访时长和成像方案中方向一致,提示PCAT衰减可能是炎症相关冠状动脉易损性的标志物。
要点
- PCAT衰减每增加5 HU,MACE风险增加(HR 1.29,95%CI 1.09-1.53)。
- 短期随访HR 1.22(95%CI 1.04-1.43),中长期方向一致但未达统计学显著。
- 标准化右冠状动脉PCAT与病变特异或多血管方法效应量相似。
核心结论
- 更高的PCAT衰减与MACE风险增加相关,在不同成像平台和随访时长中一致,似乎是炎症相关冠状动脉易损性的标志物。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE via Pubmed、Scopus和Cochrane至2025年6月,纳入17项纵向CCTA研究(n=57,862),其中7个队列(n=5,922)进入基于HU的荟萃分析;采用随机效应模型,HR标准化为每1 HU尺度并汇总为每5 HU呈现。
诊断标准与关键数值
- PCAT衰减每增加5 HU,MACE风险HR 1.29(95%CI 1.09-1.53;I²≈84%);短期随访(≤3年)HR 1.22(95%CI 1.04-1.43),中期(>3-5年)HR 1.38(95%CI 0.98-1.95),长期(≥5年)HR 1.50(95%CI 0.86-2.62),组间无显著差异;标准化右冠状动脉PCAT与病变特异或多血管方法的效应量相似;FAI、ΔFAI、HU阈值或复合/AI衍生指标的研究显示更炎症的血管周围衰减表型与更高风险相关。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 异质性I²≈84%。
- 中期随访HR 1.38(95%CI 0.98-1.95)和长期随访HR 1.50(95%CI 0.86-2.62)的置信区间跨1,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Pericoronary adipose tissue (PCAT) attenuation on coronary computed tomography angiography (CCTA) reflects local vascular inflammation, but its prognostic performance across heterogeneous imaging protocols and follow-up durations remains uncertain.
METHODS: MEDLINE via Pubmed, Scopus, and Cochrane were searched through June 2025 for longitudinal CCTA studies reporting multivariable-adjusted associations between attenuation-based PCAT metrics and major adverse cardiovascular events (MACE). Hazard ratios (HRs) were standardized to a per-1-Hounsfield unit (HU) scale and pooled using random-effects models, with estimates presented per 5 HU. Follow-up was stratified as short (≤3 years), intermediate (>3-5 years), and long-term (≥5 years). Studies evaluating fat attenuation index (FAI), change in FAI (ΔFAI), thresholds, or artificial intelligence (AI)-derived perivascular metrics were synthesized qualitatively.
RESULTS: Seventeen studies (n = 57,862) met inclusion criteria; seven cohorts (n = 5,922) contributed to the HU-based meta-analysis. Higher PCAT attenuation was associated with increased MACE risk (HR 1.29 per 5 HU; 95 % confidence interval [CI] 1.09-1.53; I2≈84 %). Across follow-up strata, effect estimates remained directionally consistent: short-term HR 1.22 per 5 HU (95 % CI 1.04-1.43), intermediate-term HR 1.38 (95 % CI 0.98-1.95), and long-term HR 1.50 (95 % CI 0.86-2.62), without significant between-group differences. Subgroup analyses showed similar effect sizes in studies using standardized right coronary artery (RCA) PCAT versus lesion-specific or multivessel approaches. Ten additional studies evaluating FAI, ΔFAI, HU thresholds, or composite or AI-based metrics showed higher risk with more inflamed perivascular attenuation phenotypes.
CONCLUSION: Higher PCAT attenuation is associated with increased MACE risk across diverse imaging platforms and follow-up horizons and appears to be a marker of inflammation-related coronary vulnerability.
引用
- Sagoo NS, Sagoo R, LeGate J, et al. Pericoronary adipose tissue attenuation on CCTA as a marker of cardiovascular risk: A systematic review and meta-analysis. Eur J Radiol. 2025. PMID: 41412070. doi:10.1016/j.ejrad.2025.112607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。